Limited Pharmacy Distribution Network for Eye Care Drug XDEMVY

Tarsus Pharmaceuticals, Inc. (Tarsus), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, announced that XDEMVY™ (lotilaner ophthalmic solution) 0.25% is now available at a limited number of pharmacies nationwide for prescription. The U.S. Food and Drug Administration (FDA) approved XDEMVY on July 24, 2023, for the treatment of Demodex blepharitis.

XDEMVY is the only FDA approved treatment to directly target Demodex mites, the root cause of Demodex blepharitis. Demodex blepharitis is characterized by redness, inflammation, missing or misdirected eyelashes, itching along the eyelid base, and the presence of collarettes.

XDEMVY is a prescription eye drop that is administered with one drop in each eye twice daily (approximately 12 hours apart) for 6 weeks. Demodex blepharitis is estimated to impact approximately 25 million eye care patients in the U.S. – or 1 out of every 12 adults.

Tarsus projects XDEMVY the initial addressable Demodex Blepharitis Market to be a multi-billion-dollar opportunity and $1B+ peak net sales potential with clear segments identified for initial ramp and future growth. XDEMVY WAC pricing of $1,850 reflects category creating product profile and pharmacoeconomic value.

Tarsus’s planned distribution model leverages high touch retail and digital pharmacies to ensure patient access. Pharmacies in the network include:

  • AllianceRx Walgreens Pharmacy
  • BlinkRx
  • Carepoint Pharmacy
  • CVS Specialty Pharmacy

Tarsus applies proven science and new technology to revolutionize treatment for patients, starting with eye care. Tarsus is also advancing its pipeline to address several diseases with high unmet need across a range of therapeutic categories, including eye care, dermatology, and infectious disease prevention.


Takeaway: Tarsus Pharmaceuticals selected the pharmacies in its XDEMVY limited distribution network to ensure patient access